Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer

Oncotarget

Volumn 7, Issue 18, 2016, Pages 25315-25327

  Wu, Jian ^a   Qin, Hongqiang ^b   Li, Ting ^a   Cheng, Kai ^b   Dong, Jiaqiang ^a   Tian, Miaomiao ^a   Chai, Na ^a   Guo, Hao ^a   Li, Jinjing ^a   You, Xin ^b   Dong, Mingming ^b   Ye, Mingliang ^b   Nie, Yongzhan ^a   Zou, Hanfa ^b   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

Author keywords

Chemoresistance; gastric cancer; Glycoprotein; Secretome analysis; Site specific glycosylation

Indexed keywords

CLU PROTEIN; GLYCOPROTEIN; L1CAM PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE AXL; SECRETORY PROTEIN; TIMP1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FUCOSYLATION; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN TARGETING; STOMACH CANCER; DRUG RESISTANCE; GLYCOSYLATION; METABOLISM; PHYSIOLOGY; PROTEOMICS; STOMACH TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; PROTEOMICS; STOMACH NEOPLASMS;

EID: 84967153413     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8287     Document Type: Article

References (63)

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016.
2. Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 2010; 6:527-537.
3. Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents. 2003; 22:188-199.
4. Wang F, Li T, Zhang B, Li H, Wu Q, Yang L, Nie Y, Wu K, Shi Y, Fan D. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun. 2013; 434:688-694.
5. Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li K, Zhou L, Sun Y, Li M, Zhou J, An Y, Wu K, Nie Y, et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014; 33:3267-3276.
6. Liu L, Sun L, Zhang H, Li Z, Ning X, Shi Y, Guo C, Han S, Wu K, Fan D. Hypoxia-mediated up-regulation of MGr1-Ag/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resistance. Int J Cancer. 2009; 124:1707-1715.
7. Shang Y, Feng B, Zhou L, Ren G, Zhang Z, Fan X, Sun Y, Luo G, Liang J, Wu K, Nie Y, Fan D. The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer. Oncotarget. 2015; doi: 10.18632/oncotarget.6374.
8. Wu Q, Yang Z, Xia L, Nie Y, Wu K, Shi Y, Fan D. Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters. Oncotarget. 2014; 5:11552-11563; doi: 10.18632/oncotarget.2594.
9. Straussman R, Morikawa T, Shee K, Barzily-RokniM, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487:500-504.
10. Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, Marais R, Sahai E. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell. 2015; 27:574-588.
11. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501:346-354.
12. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015; 27:462-472.
13. Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N, Lo RS, Massague J. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015; 520:368-372.
14. Zhang FF, Zhu YF, Zhao QN, Yang DT, Dong YP, Jiang L, Xing WX, Li XY, Xing H, Shi M, Chen Y, Bruce IC, Jin J, et al. Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance. Eur J Pharmacol. 2014; 738:83-90.
15. Choi DY, You S, Jung JH, Lee JC, Rho JK, Lee KY, Freeman MR, Kim KP, Kim J. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment. Proteomics. 2014; 14:1845-1856.
16. Xiu P, Dong X, Dong X, Xu Z, Zhu H, Liu F, Wei Z, ZhaiB, Kanwar JR, Jiang H, Li J, Sun X. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Cancer Sci. 2013; 104:375-382.
17. Huang H, Wang L, Li M, Wang X, Zhang L. Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells. World J Surg Oncol. 2014; 12:255.
18. Liu Z, Xu J, He J, Zheng Y, Li H, Lu Y, Qian J, Lin P, Weber DM, Yang J, Yi Q. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood. 2014; 124:2061-2071.
19. Yuan G, Regel I, Lian F, Friedrich T, Hitkova I, Hofheinz RD, Strobel P, Langer R, Keller G, Rocken C, Zimmermann W, Schmid RM, Ebert MPA, et al. WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. Oncogene. 2013; 32:375-387.
20. Cho HJ, Kim IK, Park SM, Baek KE, Nam IK, Park SH, Ryu KJ, Choi J, Ryu J, Hong SC, Jeong SH, Lee YJ, Ko GH, et al. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer. 2014; 135:1553-1563.
21. Huang H, Han Y, Wu J, Tian ZH, Qu LK, Shou CC. [Establishment of drug resistant cell line of MGC-803 and analysis of differential secretome]. Beijing Da Xue Xue Bao. 2014; 46:183-189.
22. Li K, Sun Z, Zheng J, Lu Y, Bian Y, Ye M, Wang X, Nie Y, Zou H, Fan D. In-depth research of multidrug resistance related cell surface glycoproteome in gastric cancer. J Proteomics. 2013; 82:130-140.
23. Lattova E, Tomanek B, Bartusik D, Perreault H. N-glycomic changes in human breast carcinoma MCF-7 and T-lymphoblastoid cells after treatment with herceptin and herceptin/Lipoplex. J Proteome Res. 2010; 9:1533-1540.
24. Lattova E, Bartusik D, Spicer V, Jellusova J, Perreault H, Tomanek B. Alterations in glycopeptides associated with herceptin treatment of human breast carcinoma mcf-7 and T-lymphoblastoid cells. Mol Cell Proteomics. 2011; 10:M111 007765.
25. Nakano M, Saldanha R, Gobel A, Kavallaris M, PackerNH. Identification of glycan structure alterations on cell membrane proteins in desoxyepothilone B resistant leukemia cells. Mol Cell Proteomics. 2011; 10:M111 009001.
26. Hoffmann M, Marx K, Reichl U, Wuhrer M, Rapp E. Site-specific O-Glycosylation Analysis of Human Blood Plasma Proteins. Mol Cell Proteomics. 2016; 15:624-641.
27. Sun S, Shah P, Eshghi ST, Yang W, Trikannad N, Yang S, Chen L, Aiyetan P, Hoti N, Zhang Z, Chan DW, Zhang H. Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides. Nat Biotechnol. 2016; 34:84-88.
28. Shah P, Wang X, Yang W, Toghi Eshghi S, Sun S, Hoti N, Chen L, Yang S, Pasay J, Rubin A, Zhang H. Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveal Glycoprotein Alteration in Protein Abundance and Glycosylation. Mol Cell Proteomics. 2015; 14:2753-2763.
29. Cheng K, Chen R, Seebun D, Ye M, Figeys D, Zou H. Large-scale characterization of intact N-glycopeptides using an automated glycoproteomic method. J Proteomics. 2014; 110:145-154.
30. Toricelli M, Melo FH, Peres GB, Silva DC, JasiulionisMG. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol Cancer. 2013; 12:22.
31. Ma H, Miao X, Ma Q, Zheng W, Zhou H, Jia L. Functional roles of glycogene and N-glycan in multidrug resistance of human breast cancer cells. IUBMB Life. 2013; 65:409-422.
32. Guo H, Dong J, Hu S, Cai X, Tang G, Dou J, Tian M, He F, Nie Y, Fan D. Biased random walk model for the prioritization of drug resistance associated proteins. Sci Rep. 2015; 5:10857.
33. Chen Z, Zhang L, Xia L, Jin Y, Wu Q, Guo H, Shang X, DouJ, Wu K, Nie Y, Fan D. Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett. 2014; 350:43-51.
34. Cheng L, Luo S, Jin C, Ma H, Zhou H, Jia L. FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death Dis. 2013; 4:e923.
35. Paccez JD, Vogelsang M, Parker MI, Zerbini LF. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int J Cancer. 2014; 134:1024-1033.
36. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014; 14:769-785.
37. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012; 44:852-860.
38. Li Y, Jia L, Liu C, Gong Y, Ren D, Wang N, Zhang X, Zhao Y. Axl as a downstream effector of TGF-beta1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma. Tumour Biol. 2015; 36:1115-1127.
39. Asiedu MK, Beauchamp-Perez FD, Ingle JN, BehrensMD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. 2014; 33:1316-1324.
40. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, et al. AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell. 2015; 27:533-546.
41. Wang Y, Xia H, Zhuang Z, Miao L, Chen X, Cai H. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. Cell Death Dis. 2014; 5:e1227.
42. Li J, Jia L, Ma ZH, Ma QH, Yang XH, Zhao YF. Axl glycosylation mediates tumor cell proliferation, invasion and lymphatic metastasis in murine hepatocellular carcinoma. World J Gastroenterol. 2012; 18:5369-5376.
43. Ren D, Li Y, Gong Y, Xu J, Miao X, Li X, Liu C, Jia L, Zhao Y. Phyllodes tumor of the breast: role of Axl and ST6GalNAcII in the development of mammary phyllodes tumors. Tumour Biol. 2014; 35:9603-9612.
44. O'Bryan JP, Fridell YW, Koski R, Varnum B, Liu ET. The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem. 1995; 270:551-557.
45. Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, Muller P, Greplova K, Valik D, Dooley S, Brostjan C, Gruenberger T, Shen J, Man K, et al. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer. 2015; 137:385-394.
46. Gustafsson A, Martuszewska D, Johansson M, Ekman C, Hafizi S, Ljungberg B, Dahlback B. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res. 2009; 15:4742-4749.
47. Yoon H, Min JK, Lee DG, Kim DG, Koh SS, Hong HJ. L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells. Cancer Lett. 2012; 316:70-76.
48. Kiefel H, Bondong S, Erbe-Hoffmann N, HazinJ, Riedle S, Wolf J, Pfeifer M, Arlt A, Schafer H, Muerkoster SS, Altevogt P. L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression. Oncogene. 2010; 29:4766-4778.
49. Sebens Muerkoster S, Werbing V, Sipos B, Debus MA, WittM, Grossmann M, Leisner D, Kotteritzsch J, Kappes H, Kloppel G, Altevogt P, Folsch UR, Schafer H. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene. 2007; 26:2759-2768.
50. Bjerre C, Vinther L, Belling KC, Wurtz SO, YadavR, Lademann U, Rigina O, Do KN, Ditzel HJ, LykkesfeldtAE, Wang J, Nielsen HB, Brunner N, et al. TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression. Tumour Biol. 2013; 34:3839-3851.
51. Song T, Dou C, Jia Y, Tu K, Zheng X. TIMP-1 activated carcinoma-associated fibroblasts inhibit tumor apoptosis by activating SDF1/CXCR4 signaling in hepatocellular carcinoma. Oncotarget. 2015; 6:12061-12079. doi: 10.18632/oncotarget.3616.
52. Schrohl AS, Meijer-van Gelder ME, Holten-AndersenMN, Christensen IJ, Look MP, Mouridsen HT, Brunner N, Foekens JA. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res. 2006; 12:7054-7058.
53. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol. 2005; 7:909-915.
54. Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, WelchWR, Choi YK, Birrer MJ, Mok SC, Wong KK. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia. 2008; 10:964-972.
55. Kim YS, Ahn YH, Song KJ, Kang JG, Lee JH, JeonSK, Kim HC, Yoo JS, Ko JH. Overexpression and beta- 1, 6-N-acetylglucosaminylation-initiated aberrant glycosylation of TIMP-1: a "double whammy" strategy in colon cancer progression. J Biol Chem. 2012; 287:32467-32478.
56. Kim H, Saldova R, Park JH, Lee YH, Harvey DJ, WormaldMR, Wynne K, Elia G, Kim HJ, Rudd PM, Lee ST. The presence of outer arm fucose residues on the N-glycans of tissue inhibitor of metalloproteinases-1 reduces its activity. J Proteome Res. 2013; 12:3547-3560.
57. Rohne P, Prochnow H, Wolf S, Renner B, Koch-BrandtC. The chaperone activity of clusterin is dependent on glycosylation and redox environment. Cell Physiol Biochem. 2014; 34:1626-1639.
58. Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, MannM. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics. 2014; 13:2513-2526.
59. Jiang X, Ye M, Cheng K, Zou H. ArMone: a software suite specially designed for processing and analysis of phosphoproteome data. J Proteome Res. 2010; 9:2743-2751.
60. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods. 2011; 8:785-786.
61. Bendtsen JD, Jensen LJ, Blom N, Von Heijne G, Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel. 2004; 17:349-356.
62. Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc. 2013; 8:1551-1566.
63. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513:202-209.